A history of blood clots is not usually any reason to avoid the AstraZeneca vaccine

As hematologists, we look after many patients who have had blood clots in the past or take blood thinners. They often ask: “should I have the AstraZeneca vaccine?” The answer is usually a definitive “yes.” The blood clots we’ve seen following the AstraZeneca vaccine are completely different to other types of blood clots, such as deep vein thrombosis or a […]

Read more

Study: No major difference in mortality between patients treated with drug-coated and non-drug-coated devices

Peripheral artery disease (PAD), or blockages in the arteries outside of the heart, affects more than 200 million people worldwide and 12.5 million people in the United States. Patients with this circulatory disorder may develop severe leg pain or unhealing wounds that require a minimally invasive revascularization procedure to open the blood vessels to improve blood flow. For nearly a […]

Read more

Mild Covid-19 infection not likely to cause lasting damage to structure or function of the heart

Mild Covid-19 infection is very unlikely to cause lasting damage to the structure or function of the heart, according to a study led by UCL (University College London) researchers and funded by the British Heart Foundation (BHF) and Barts Charity. The researchers say the results, published in JACC Cardiovascular Imaging, should reassure the public, as they relate to the vast […]

Read more

Woman had three brain surgeries due to blood clots after J&J vaccine

Vegas woman, 18, was placed in a coma and had to undergo THREE brain surgeries for blood clots one week after getting J&J COVID vaccine Emma Burkey, 18, of Las Vegas, Nevada, received the Johnson & Johnson coronavirus vaccine on April 1 One week later, she started experiencing seizures and was rushed to St Rose Dominican Hospital Burkey was airlifted […]

Read more

Immune tolerance in hemophilia can be modulated by B cell activating factor

A group of scientists have just made a key discovery that could prevent and eradicate immune responses that lead to treatment failure in about one-third of people with severe hemophilia A. Hemophilia is the most common severe inherited bleeding disorder in men. The disease affects 1 in 10,000 males worldwide and results from deficiency of blood clotting factor VIII (FVIII). […]

Read more

Anti-diabetic drug metformin inhibits disease progression in Alport syndrome mouse model

Researchers from Kumamoto University (Japan) have found that the anti-diabetic drug metformin significantly prolongs the survival of mice in a model that simulates the pathology of non-diabetic chronic kidney disease (ND-CKD) by ameliorating pathological conditions like reduced kidney function, glomerular damage, inflammation and fibrosis. Metformin's mechanism is different from existing therapeutics which only treat symptoms, such as the blood pressure […]

Read more

COVID vaccines: Passports, blood clots and changing trust in government

Four in 10 people think those without a COVID-19 vaccination will be discriminated against, while around a quarter of the public have concerns about vaccine passports, according to a new study. The research, by the University of Bristol and King’s College London, also finds that three in ten people say the vaccine rollout has increased their trust in the UK […]

Read more

Study offers localized treatment direction for a cause of Crohn's disease

People with Crohn's disease are typically treated with powerful anti-inflammatory medications that act throughout their body, not just in their digestive tract, creating the potential for unintended, and often serious, side effects. New research from the lab of Mark Sundrud, PhD, at Scripps Research, Florida suggests a more targeted treatment approach is possible. Crohn's disease develops from chronic inflammation in […]

Read more

Another promising approach for hard-to-treat blood cancers

For patients with some hard-to-treat blood cancers, a simple “off-the-shelf” immunotherapy is achieving promising results. A clinical trial of the developmental drug Glofitamab has shown it can produce a durable “complete response”—meaning the cancer became undetectable—in patients with relapsed or treatment resistant B-cell lymphomas. One option for these patients is CAR T-cell therapy—also an immunotherapy but one which involves collecting […]

Read more
1 2 3 19